Whether both classes of GATA3 mutationshave the same effect on ER transcriptional activity and tumour outcome is currentlyunclear, but recent gene editing tools, such as CRISPR technologies, will permitinvestigation of these questions. This evidence concerns the gene GATA3 and neoplasm.